A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Gabriel N. Hortobágyi; Aleksandra Łacko; Joohyuk Sohn; F. Melo Cruz; Manuel Ruíz Borrego; Alexey Manikhas; Yeon H. Park; Daniil Stroyakovskiy; Denise A. Yardley; C.-S. Huang; P.A. Fasching; J. Crown; A. Bardia; S. Chia; Sun Im; M. Martín; Sherene Loi; B. Xu; Sara A. Hurvitz; Carlos H. Barrios; M. Untch; R Moroose; F. Visco; Federico Parnizari; J.P. Zarate; Zheng Li; Simon Waters; A. Chakravartty; D. Slamon

doi:10.1016/j.annonc.2024.10.015

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

With longer follow-up and most patients off ribociclib, NATALEE continues to demonstrate iDFS benefit with ribociclib plus NSAI over NSAI alone in the overall population and across key subgroups. Observed adverse events remained stable.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hortobágyi et al. (2024) studied this question.

synapsesocial.com/papers/69de72297ed287395e558d64 https://doi.org/10.1016/j.annonc.2024.10.015

View Full Paper

Ask AI

Bookmark

Share

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ask about this paper

Abstract

Discussion

Cite This Study

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading